A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study

• Status: Completed
• Trial end date: 2016-01-29
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taro Pharmaceuticals USA

Criteria

Inclusion Criteria:

• Male or non-pregnant, non-lactating females age 12 and older.

• Clinical diagnosis of moderate to severe scalp psoriasis, defined by a Investigator's Global Assessment score of at least 3 at screening.

Exclusion Criteria:

• Under 12 years of age.

• Patients whose scalp and/or non-scalp psoriasis necessitates systemic or other concomitant topical therapies during the study.

• Has a scalp skin condition that would interfere with the diagnosis or assessment of plaque psoriasis of the scalp.